Organization
Halozyme Therapeutics, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Halozyme Therapeutics, Inc.
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will ...
... If you want a Stock Review on ECYT, EDIT, HALO, or ILMN then come over tohttp://dailystocktracker.com/register/and sign up for your free customized ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will present nonclinical data at the ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a multi-arm clinical trial evaluating ...
... Coordinator, Corporate Communications, Ionis Pharmaceuticals) Vice President-Treasurer Chris Burton (Director, Investor Relations, Halozyme Therapeutics) Vice President-Communications Jessica Dyas (Account Manager, Canale Communications) Â Vice President-Sponsorship ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced initiation of a clinical trial evaluating its investigational ...
... SAN DIEGO. - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will ...
... reflects healthy market breadth, or participation." Oracle Corporation (NYSE: ORCL), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Nordstrom, Inc. (NYSE: JWN), Aldeyra Therapeutics Inc. (NASDAQ: ALDX), Teva ...
... fund’s attempt to buy the chip maker for $1.3 billion. Shares of Halozyme Therapeutics gained 18% premarket. The biotechnology firm announced a license agreement with ...
... Bristol-Myers Squibb has paid Halozyme $105 million upfront to access drug delivery technology. The agreement positions Bristol-Myers ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today it licensed its ENHANZE® drug-delivery technology to Roche ...
... If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over tohttp://dailystocktracker.com/register/and sign up for your free ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will ...
... were used to increase BB Biotech's shareholdings in Alexion, Alder, Avexis, Esperion, Halozyme, Intra-Cellular, Neurocrine Biosciences and Radius Health. There was plenty of positive company ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a multi-arm clinical trial evaluating ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will ...
... Results from Halozyme Therapeutics (NASDAQ: HALO) Phase 2 randomized, multi-center clinical trial in pancreas cancer patients ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤